Erlotinib

Non-Small Cell Lung Cancer

Erlotinib is used to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to nearby tissues or other parts of the body. It is specifically indicated for patients whose cancer cells have certain genetic mutations in the epidermal growth factor receptor (EGFR) gene, such as exon 19 deletions or exon 21 substitution mutations.

Depending on the patient's situation, erlotinib may be used as:

• A first-line treatment for metastatic cancer.
• Maintenance therapy for patients whose cancer has not worsened after initial chemotherapy.
• Treatment for cancer that has progressed after at least one previous chemotherapy session.

It may also be used in combination with other medications, such as ramucirumab, for the initial treatment of certain metastatic lung cancers.

Pancreatic Cancer

Erlotinib is also prescribed for patients with advanced pancreatic cancer that has spread or cannot be surgically removed. For this condition, it is used in combination with another chemotherapy medication called gemcitabine.

Mechanism of Action

Erlotinib belongs to a class of medications called tyrosine kinase inhibitors. It is designed to target and block the activity of a protein called the epidermal growth factor receptor (EGFR). This protein is found on the surface of both normal cells and cancer cells.

In certain types of cancer, the EGFR protein is overactive or mutated, sending continuous signals to the cell to grow, divide, and spread. By attaching to this protein, erlotinib interferes with these signals. This process helps to:

• Slow down the growth of the tumor.
• Stop cancer cells from multiplying.
• Prevent the cancer from spreading to other parts of the body.

Because erlotinib targets specific proteins involved in cell growth, it is considered a targeted therapy rather than a traditional chemotherapy, which typically affects all rapidly dividing cells in the body.

Common Side Effects

The most frequent side effects associated with erlotinib include:

• Diarrhea
• Skin rash, often appearing like acne
• Dry, itchy, or cracked skin
• Loss of appetite and weight loss
• Nausea and vomiting
• Mouth sores
• Fatigue or unusual weakness
• Cough

Serious Side Effects

While less common, some side effects can be life-threatening. Seek medical attention immediately for:

• Severe or persistent diarrhea
• Severe skin reactions, including blistering, peeling, or intense pain
• Signs of liver damage, such as yellowing of the eyes or skin, dark urine, or light-colored stools
• New or worsening lung problems, including sudden shortness of breath, cough, or fever
• Severe stomach or abdominal pain, which may indicate a tear in the wall of the stomach or intestines
• Eye pain, redness, or changes in vision
• Unusual bleeding or bruising
• Signs of kidney problems, such as decreased urination or swelling in the legs and feet

Lung and Respiratory Issues

Serious and sometimes fatal lung conditions, such as interstitial lung disease (ILD), have been reported in patients taking erlotinib. Symptoms include the sudden onset of new or worsening shortness of breath, cough, or fever. Treatment is typically interrupted or discontinued if these symptoms occur.

Liver and Kidney Function

Erlotinib can cause liver failure or hepatorenal syndrome, particularly in individuals with pre-existing liver impairment. Regular blood tests are used to monitor liver and kidney function during treatment. Severe diarrhea, which is a common side effect, can also lead to dehydration and subsequent kidney injury.

Gastrointestinal Risks

There is a risk of gastrointestinal perforation, which is a hole in the wall of the stomach or intestines. This risk may be increased for individuals also taking certain medications, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or certain types of chemotherapy.

Skin and Eye Reactions

Severe skin conditions, including blistering or peeling (such as Stevens-Johnson syndrome or toxic epidermal necrolysis), have occurred. Additionally, erlotinib may cause eye problems such as corneal perforation or ulceration. New or worsening eye pain, redness, or vision changes require medical evaluation.

Drug Interactions and Lifestyle Factors

• Blood Thinners: Taking erlotinib with warfarin or other coumarin-derived anticoagulants increases the risk of bleeding.
• Smoking: Cigarette smoking significantly reduces the concentration of erlotinib in the blood, which may make the medication less effective.

Pregnancy and Fetal Harm

Erlotinib can cause harm to a developing fetus. Effective contraception is recommended for individuals of reproductive potential during treatment and for at least one month after the final dose. Breastfeeding is generally not recommended during treatment and for two weeks following the last dose.

Pregnancy

Erlotinib may cause fetal harm when administered to a pregnant woman. Animal studies have shown that the medication can increase the risk of pregnancy loss and result in lower birth weights. Because of these risks, healthcare providers typically advise that erlotinib should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Individuals who can become pregnant are advised to use effective contraception during treatment and for at least one month after the final dose. If a patient becomes pregnant while taking this medication, they should contact their healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known whether erlotinib passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least two weeks after the final dose. Patients should consult with their healthcare team to discuss the best way to feed their infant during and after treatment.

Dosage Forms

Erlotinib is provided as a tablet for oral administration. These tablets are film-coated and are intended to be swallowed whole.

• Oral tablet

FDA Approval History

Erlotinib was first approved by the U.S. Food and Drug Administration (FDA) in November 2004. It was initially indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen. Over time, the FDA updated its indications to focus on patients whose tumors harbor specific genetic mutations.

Approved Indications

The FDA has approved erlotinib for the following specific uses:

• Non-Small Cell Lung Cancer (NSCLC): It is used as a first-line treatment, maintenance treatment, or second-line treatment for patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
• Combination Therapy for NSCLC: In 2020, the FDA approved erlotinib for use in combination with ramucirumab for the first-line treatment of metastatic NSCLC in patients with specific EGFR mutations.
• Pancreatic Cancer: It is approved for use in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Regulatory Status and Safety

Erlotinib is a prescription-only medication. It does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program. While the medication does not carry a Boxed Warning, the FDA requires the manufacturer to include warnings regarding serious potential risks, including interstitial lung disease, renal failure, hepatotoxicity (liver toxicity), and gastrointestinal perforation. Generic versions of erlotinib tablets are FDA-approved and available.

Generic and Brand-Name Availability

Erlotinib is available as a generic medication and under the brand name Tarceva. Generic versions are typically more affordable than brand-name drugs. Choosing the generic form, when available and approved by a healthcare provider, can significantly reduce out-of-pocket expenses.

Insurance and Medicare Coverage

Most insurance plans, including Medicare Part D and Medicare Advantage, provide coverage for erlotinib. However, because it is a specialty oncology medication, it is often placed on a higher cost-sharing tier. This may result in a higher copayment or coinsurance amount. Many insurance companies also require prior authorization before they will approve coverage for the medication.

Financial Assistance Programs

For patients who are uninsured or have high out-of-pocket costs, several resources may be available:

• Manufacturer Assistance: Pharmaceutical companies that produce erlotinib may offer patient assistance programs or copay savings cards to eligible individuals.
• Support Foundations: Non-profit organizations sometimes provide financial grants to help cancer patients cover the costs of specialty treatments.

Patients are encouraged to speak with their oncology team or a specialty pharmacist to explore available financial support options and to verify coverage details with their insurance provider.